Hemostemix Launches Enhanced HubSpot-Powered Websites to Support Global Marketing & Sales of ACP-01 for No-Option Patients
Hemostemix (OTCQB: HMTXF) has announced the launch of its upgraded HubSpot-powered corporate websites, marking a significant advancement in its digital marketing capabilities. The company, which offers VesCell™ (ACP-01) stem cell therapy for various conditions including peripheral arterial disease and heart conditions, has transformed its static websites into an integrated marketing and CRM sales platform.
The new platform features AI-driven patient engagement, HIPAA-compliant portals, and automated administrative workflows. Key improvements include streamlined lead generation, efficient patient intake, and targeted clinical partner outreach in Florida, where the therapy is available under SB 1768 for patients with life-threatening conditions who have exhausted standard treatment options.
The company expects to achieve 20% administrative cost savings and improved patient access through multilingual support and AI-powered capabilities. The platform will support Hemostemix's global expansion plans while maintaining regulatory compliance.
Hemostemix (OTCQB: HMTXF) ha annunciato il lancio dei suoi siti aziendali potenziati, basati su HubSpot, segnando un importante progresso nelle capacità di marketing digitale. L'azienda, che offre la terapia con cellule staminali VesCell™ (ACP-01) per varie condizioni, tra cui la malattia periferica arteriosa e patologie cardiache, ha trasformato i propri siti statici in una piattaforma integrata di marketing e CRM per le vendite.
La nuova piattaforma include coinvolgimento dei pazienti guidato dall'IA, portali conformi a HIPAA e flussi di lavoro amministrativi automatizzati. I miglioramenti principali comprendono una generazione di lead più efficiente, un intake pazienti ottimizzato e un outreach mirato ai partner clinici in Florida, dove la terapia è disponibile ai sensi della SB 1768 per pazienti con condizioni potenzialmente letali che hanno esaurito le opzioni terapeutiche standard.
L'azienda prevede di conseguire un risparmio del 20% sui costi amministrativi e di migliorare l'accesso dei pazienti grazie al supporto multilingue e alle funzionalità potenziate dall'IA. La piattaforma sosterrà i piani di espansione globale di Hemostemix mantenendo la conformità normativa.
Hemostemix (OTCQB: HMTXF) ha anunciado el lanzamiento de sus sitios corporativos mejorados, impulsados por HubSpot, marcando un avance significativo en sus capacidades de marketing digital. La compañía, que ofrece la terapia con células madre VesCell™ (ACP-01) para diversas afecciones, incluidas la enfermedad arterial periférica y problemas cardíacos, ha transformado sus sitios estáticos en una plataforma integrada de marketing y CRM para ventas.
La nueva plataforma incluye interacción con pacientes impulsada por IA, portales compatibles con HIPAA y flujos de trabajo administrativos automatizados. Las mejoras clave abarcan generación de leads más ágil, un proceso de admisión de pacientes más eficiente y alcance dirigido a socios clínicos en Florida, donde la terapia está disponible bajo la SB 1768 para pacientes con afecciones potencialmente mortales que han agotado las opciones de tratamiento estándar.
La compañía espera lograr un ahorro del 20% en costos administrativos y mejorar el acceso de los pacientes mediante soporte multilingüe y capacidades potenciadas por IA. La plataforma respaldará los planes de expansión global de Hemostemix manteniendo el cumplimiento regulatorio.
Hemostemix (OTCQB: HMTXF)는 HubSpot 기반의 업그레이드된 기업 웹사이트를 출시했다고 발표하며 디지털 마케팅 역량에서 중요한 진전을 이뤘습니다. 말초동맥질환 및 심장 질환 등을 포함한 다양한 상태에 대한 줄기세포 치료제 VesCell™ (ACP-01)을 제공하는 이 회사는 정적 웹사이트를 통합 마케팅 및 CRM 영업 플랫폼으로 전환했습니다.
새 플랫폼은 AI 기반 환자 참여, HIPAA 준수 포털 및 자동화된 행정 워크플로를 갖추고 있습니다. 주요 개선 사항으로는 간소화된 리드 생성, 효율적인 환자 접수, 그리고 표준 치료 옵션을 소진한 생명 위협적 상태의 환자에게 해당 치료가 제공되는 플로리다의 임상 파트너 대상 타깃 아웃리치가 포함됩니다(SB 1768에 따라 제공).
회사는 행정비용 20% 절감과 다국어 지원 및 AI 기반 기능을 통한 환자 접근성 향상을 기대하고 있습니다. 이 플랫폼은 규제 준수를 유지하면서 Hemostemix의 글로벌 확장 계획을 지원할 것입니다.
Hemostemix (OTCQB: HMTXF) a annoncé le lancement de ses sites corporatifs améliorés, propulsés par HubSpot, marquant une avancée significative de ses capacités de marketing numérique. La société, qui propose la thérapie par cellules souches VesCell™ (ACP-01) pour diverses affections, y compris les maladies artérielles périphériques et les affections cardiaques, a transformé ses sites statiques en une plateforme intégrée de marketing et de CRM commercial.
La nouvelle plateforme intègre l'engagement des patients piloté par l'IA, des portails conformes à la HIPAA et des flux de travail administratifs automatisés. Les améliorations clés comprennent une génération de leads simplifiée, un accueil des patients plus efficace et une prospection ciblée des partenaires cliniques en Floride, où la thérapie est disponible en vertu de la SB 1768 pour les patients atteints d'affections potentiellement mortelles ayant épuisé les options de traitement standards.
La société prévoit de réaliser 20 % d'économies sur les coûts administratifs et d'améliorer l'accès des patients grâce au support multilingue et aux capacités renforcées par l'IA. La plateforme soutiendra les plans d'expansion mondiale d'Hemostemix tout en maintenant la conformité réglementaire.
Hemostemix (OTCQB: HMTXF) hat den Start seiner auf HubSpot basierenden, verbesserten Unternehmenswebsites bekannt gegeben und damit einen bedeutenden Fortschritt bei seinen digitalen Marketingfähigkeiten erzielt. Das Unternehmen, das die Stammzelltherapie VesCell™ (ACP-01) für verschiedene Erkrankungen, darunter periphere arterielle Verschlusskrankheit und Herzleiden, anbietet, hat seine statischen Websites in eine integrierte Marketing- und CRM-Vertriebsplattform verwandelt.
Die neue Plattform bietet KI-gestaltete Patientenansprache, HIPAA-konforme Portale und automatisierte administrative Workflows. Wichtige Verbesserungen umfassen optimierte Leadgenerierung, effiziente Patientenaufnahme und gezielte Ansprache klinischer Partner in Florida, wo die Therapie gemäß SB 1768 für Patienten mit lebensbedrohlichen Zuständen verfügbar ist, die alle Standardbehandlungen ausgeschöpft haben.
Das Unternehmen rechnet mit 20% Einsparung bei Verwaltungskosten und verbessertem Patientenzugang durch mehrsprachige Unterstützung und KI-Funktionen. Die Plattform wird Hemostemix' globale Expansionspläne unterstützen und gleichzeitig die regulatorische Compliance wahren.
- Implementation of AI-powered automation expected to reduce administrative costs by 20%
- Enhanced patient access through multilingual support and AI-powered capabilities
- Integration of HIPAA-compliant patient engagement systems
- Real-time analytics and sales funnel tracking capabilities
- Streamlined operations for faster patient intake and treatment matching
- Significant investment in new technology infrastructure with ROI yet to be proven
- Success depends on effective adoption by healthcare providers and patients
Calgary, Alberta--(Newsfile Corp. - September 9, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, announces the launch of a newly upgraded corporate website, fully integrated by HubSpot, representing a significant improvement in regulatory compliant marketing and sales functionalities.
Under physician order, following informed consent, Florida's law SB 1768 permits the use of VesCell™ in patients with life-threatening or debilitating conditions who have exhausted standard-of-care treatment options.
Website Comparison: Then vs. Now
- Current Version (Today Built on HubSpot):
As compared to static information, the new websites harnesses HubSpot infrastructure and AI-powered functionalities to deliver best-in-class marketing, sales, and engagement efficiencies. Key enhancements include:
- Automated Administrative Workflows: HubSpot-integrated AI agents and Hemostemix salesman will manage scheduling, billing, and follow-ups-projected to reduce operational overhead.
- AI-Driven Patient and Clinician Engagement: Patient portals will now include HIPAA-compliant patient engagement, including AI Agent support, patient-treatment by clinic, and trial-recruitment matching tools designed to enhance the user experience.
How Marketing & Sales Teams Will Leverage the New Platform
This upgraded digital framework positions Hemostemix to significantly accelerate ACP-01 adoption in Florida and other jurisdictions offering compassionate access:
Streamlined Lead Generation & Nurturing:
HubSpot's CRM and inbound marketing tools provide dashboards for tracking physician outreach, patient inquiries, and clinic onboarding.Efficient Patient Intake & Scheduling:
AI-powered scheduling and automated follow-up workflows allow rapid response to no-option patient referrals, significantly increasing hands-on patient interactions.Targeted Clinical Partner Outreach in Florida:
Focused content campaigns will be deployed by medical speciality. For example, vascular surgeons, and cardiologists, enabling the recent expansion of the marketing team dedicated to Florida operations to build expertise by disease type and treatment specialist.Seamless Trial Matching & Onboarding:
AI agents filter patient eligibility by patient self-identification, facilitate match to treatment protocols, and assist with logistics across jurisdictions.Operational Monitoring & Scalability:
Real-time analytics-powered by HubSpot's dashboards-track campaign performance, patient engagement metrics, and sales funnels, allowing management to scale deployment to matched with manufacturing capacity.
Strategic Impact
Enhanced Cost Efficiency: Administrative savings of up to 20 % translate into more resource allocation for business development.
Improved Patient Access: Faster intake, AI-powered support, and multilingual chatbot capabilities increase reach to no-option patients in their language of choice, in regulatory-permissive environments.
Sales Growth: Integrated workflows support deployment into geographic markets to fuel marketing and sales efforts of ACP-01
Forward Outlook
The upgraded websites are a strategic cornerstone in Hemostemix's commercialization roadmap supporting rapid patient intake response, while enabling stronger governance and compliance. As regulatory opportunities evolve jurisdiction by jurisdiction, this digital foundation ensures Hemostemix is well-positioned to scale to serve vulnerable patient populations globally, compliantly.
Summary for Shareholders
Website Evolution: hemostemix.com and Vescell.health were shifted from static info-only presence to an interactive, HubSpot-enabled marketing and CRM sales platform.
Capabilities Gained: Automation, AI engagement, optimized workflows, and analytics.
Business Leverage: Supports Florida-focused physician and patient outreach, compassionate-use sales, and scalable global expansion.
Operational and Financial Benefits: Tools for the Company's multi-lingual marketing campaigns and global sales growth within a one-write sales funnel that populates management's dashboard.
"This amplifies the impact of recent financings," stated Thomas Smeenk, CEO. "In this one step we moved from a static website to an integrated marketing and sales platform that dashboards activities and the sales funnel results in real-time," Smeenk said.
ABOUT HEMOSTEMIX
Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell™ (ACP-01). A recent peer-reviewed article in Cells (June 29, 2025) provides the scientific foundation for how ACP-01 and NCP-01 may enhance brain-computer interface performance by reducing inflammation, fostering angiogenesis and synaptic plasticity, potentially extending implant longevity. Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of
For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder: EM: tsmeenk@hemostemix.com / PH: 905-580-4170
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to VesCell.Health and hemostemix.com in furtherance of the sales of VesCell™ (ACP-01), and the commercialization of ACP-01 via the sale and financing of compassionate treatments under Florida SB 1768. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedarplus.ca. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/265659
FAQ
What new features did Hemostemix (HMTXF) add to its website platform in September 2025?
How will the new HubSpot platform benefit HMTXF's operations?
Where is Hemostemix's VesCell therapy currently available?
What medical conditions can be treated with Hemostemix's VesCell therapy?
How will the new website platform impact patient access to VesCell therapy?
